Monogenic diabetes and neonatal diabetes

The idea that organises the whole topic is a single-gene beta-cell defect that masquerades as type 1 or type 2 diabetes. Because the problem sits in one gene, the family history runs in an autosomal-dominant line, the islet autoantibodies are absent, the C-peptide survives beyond any honeymoon, and — critically — the correct treatment is set by which gene is at fault. Glucokinase-MODY rarely needs a drug at all, the HNF1A and HNF4A forms are exquisitely sensitive to a low-dose sulfonylurea, and the potassium-channel neonatal diabetes responds better to oral glibenclamide than to insulin. ^{[1] [4]}

This page covers the suspicion, confirmation and gene-matched treatment of monogenic diabetes in children: the neonatal diabetes that appears under six months, the GCK and HNF1A/HNF4A MODY subtypes that change the drug, the HNF1B form that brings the kidneys and pancreas with it, the genetic testing pathway, and the lifelong team care that follows a correct molecular label. It links to the dedicated leaves for type 1 and type 2 diabetes rather than repeating their full pathways. ^[2]

Overview & Definition

Monogenic diabetes is diabetes arising from a mutation in a single gene that governs beta-cell development, insulin production, or the glucose-sensing and secretion machinery. It accounts for an estimated one to four percent of childhood diabetes, although most affected children are mislabelled as having type 1 or type 2 for years before the molecular diagnosis is made. ^{[1] [5]}

The clinically useful distinction at presentation is between the two broad monogenic families. Neonatal diabetes mellitus is hyperglycaemia requiring insulin that begins in the first six months of life, a window in which autoimmune type 1 diabetes is vanishingly rare, so any diabetes here is presumed monogenic until genetics proves otherwise. Maturity-onset diabetes of the young is the monogenic diabetes of later infancy, childhood and adolescence, classically autosomal dominant, antibody-negative, and associated with preserved endogenous insulin. ^{[2] [7]}

Why the distinction from type 1 and type 2 matters is purely therapeutic. Type 1 diabetes demands insulin from the outset. Type 2 diabetes is managed with lifestyle and metformin, then escalating therapy. Monogenic diabetes is managed by gene: GCK-MODY usually needs no drug, HNF1A and HNF4A MODY respond to a sulfonylurea, and potassium-channel neonatal diabetes shifts from insulin to glibenclamide. A wrong label means a wrong drug, decades of unnecessary injections, and avoidable hypoglycaemia. ^{[1] [4]}

References12ShowHide

1. [1]Hattersley AT; Greeley SAW; Polak M; et al ISPAD Clinical Practice Consensus Guidelines 2018: The diagnosis and management of monogenic diabetes in children and adolescents. Pediatr Diabetes, 2018.PMID 30225972
2. [2]Rubio-Cabezas O; Hattersley AT; Njølstad PR; et al ISPAD Clinical Practice Consensus Guidelines 2014. The diagnosis and management of monogenic diabetes in children and adolescents. Pediatr Diabetes, 2014.PMID 25182307
3. [3]Gloyn AL; Pearson ER; Antcliff JF; et al Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N Engl J Med, 2004.PMID 15115830
4. [4]Pearson ER; Flechtner I; Njølstad PR; et al Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med, 2006.PMID 16885550
5. [5]Pihoker C; Gilliam LK; Ellard S; et al Prevalence, characteristics and clinical diagnosis of maturity onset diabetes of the young due to mutations in HNF1A, HNF4A, and glucokinase: results from the SEARCH for Diabetes in Youth. J Clin Endocrinol Metab, 2013.PMID 23771925
6. [6]Shields BM; Hicks S; Shepherd MH; et al Population-Based Assessment of a Biomarker-Based Screening Pathway to Aid Diagnosis of Monogenic Diabetes in Young-Onset Patients. Diabetes Care, 2017.PMID 28701371
7. [7]Flanagan SE; Edghill EL; Gloyn AL; et al Mutations in KCNJ11, which encodes Kir6.2, are a common cause of diabetes diagnosed in the first 6 months of life, with the phenotype determined by genotype. Diabetologia, 2006.PMID 16609879
8. [8]Hughes AE; Maguiness S; Balci S; et al Identification of GCK-maturity-onset diabetes of the young in cases of neonatal hyperglycemia: A case series and review of clinical features. Pediatr Diabetes, 2021.PMID 34085361
9. [9]Bowman P; Flanagan SE; Edghill EL; et al Heterozygous ABCC8 mutations are a cause of MODY. Diabetologia, 2012.PMID 21989597
10. [10]Edghill EL; Bingham C; Ellard S; Hattersley AT Permanent neonatal diabetes due to activating mutations in ABCC8 and KCNJ11. Rev Endocr Metab Disord, 2010.PMID 20922570
11. [11]Rapini N; Martinez TF; Bizzarri C; et al The Changing Landscape of Neonatal Diabetes Mellitus in Italy Between 2003 and 2022. J Clin Endocrinol Metab, 2024.PMID 38408297
12. [12]De Franco E; Flanagan SE; Houghton JAL; et al Biallelic PDX1 (insulin promoter factor 1) mutations causing neonatal diabetes without exocrine pancreatic insufficiency. Diabet Med, 2013.PMID 23320570